While etanercept carries a decreased risk relative to other similar TNF inhibitors, clinicians must remain vigilant in recognizing and promptly treating RHS to optimize outcomes and mitigate long-term complications. This evidence concerns the gene TNF and leukocyte adhesion deficiency type II.